Sudden onset of diabetic ketoacidosis during consensus interferon therapy for chronic viral hepatitis C.
Interferon (IFN)-alpha, used for the treatment of chronic hepatitis C, has rarely been associated with the development of diabetes. Consensus interferon (CIFN), which is used for nonresponders, has not been associated with this complication. We describe the first case of new onset diabetes in a patient on CIFN. A 50-year-old man with chronic hepatitis C and no prior diabetes was started on IFN-alpha. After 24 weeks with a detectable viral load, he was switched to CIFN. Four weeks later, he presented in diabetic ketoacidosis which resolved with appropriate therapy without any ascertainable etiology (glutamic acid decarboxylase negative). Within 9 months he was off insulin, and is off all diabetic medications with an HgA1c of 5.6% 2 years after the episode.